In Industry News

The European Medicines Agency (EMA) has launched its new PRIME (PRIority MEdicines) scheme to strengthen support to medicines that target an unmet medical need.

PRIME builds on the existing regulatory framework and available tools such as scientific advice and accelerated assessment. A PRIME medicine is expected to benefit from accelerated assessment at the time of an application for marketing authorisation.

For more information about the PRIME scheme, click here to visit the EMA website.

Recent Posts